Sialic acidity present in creatures protects farm children from bronchial asthma

It’s a known proven fact that microbes on farms safeguard children from bronchial asthma and allergic reactions. But non-microbial molecules may have a protective effect: Immunologists in the College of Zurich have proven that the sialic acidity present in farm creatures works well against inflammation of lung tissue. This research reveals a multitude of perspectives to prevent allergic reactions.

Increasing numbers of people are afflicted by allergic reactions and bronchial asthma. Previously decades, these illnesses have massively elevated in industrialized countries. Today, about 30 % of kids have allergic reactions – except for farm children. Among farm children, the condition is growing less dramatically compared to the situation of the buddies who reside in exactly the same village, although not on the farm. Microbes that exist in greater amounts and greater diversity on farms safeguard farm children from allergic reactions and bronchial asthma. An atmosphere that isn’t highly hygienic includes a positive impact on the introduction of the defense mechanisms because it learns to not respond to harmless materials out of the box the situation with allergic reactions.

A sialic acidity functions as protection

Not just microbes safeguard against bronchial asthma obviously, but additionally farm creatures: Petting cats and cows and consuming farm milk may also prevent bronchial asthma, because the group of researchers headed up by Remo Frei from the Swiss Institute of Allergy and Bronchial asthma Research in the College of Zurich in cooperation using the Center for Allergy Research and Education (CK-CARE) in Davos and also the Children’s Hospital of Eastern Europe in St. Gallen: “Early childhood connection with creatures and the intake of food of animal origin appears to manage the inflammatory reactions from the defense mechanisms,” states immunologist Frei. His study implies that a non-microbial substance, a sialic acidity, accounts for this mechanism. It is endemic in vertebrates – and for that reason in lots of farm creatures – but missing within the human organism: N-Glycolylneuraminic acidity (Neu5Gc).

Antibodies as measure for connection with farm creatures

With different genetic mutation, humans don’t produce Neu5Gc. They are able to absorb sialic acidity through connection with creatures or when you eat food of animal origin and integrate it to their glycoproteins. Connection with Neu5Gc triggers an antibody reaction in humans which could behave as a stride for connection with Neu5Gc, that’s, with farm creatures. They brought by Remo Frei have measured the concentrations of Neu5Gc antibodies within the serum examples of children collected inside the scope of two epidemiological studies financed through the Eu (PARSIFAL and PASTURE study).

Data comparison in excess of a 1000 children

Like a comparison from the Neu5Gc antibody power of more than a 1000 children and the appearance of bronchial asthma has clearly proven, “Farm children have numerous more antibodies against Neu5Gc within their bloodstream – and kids with increased antibodies endured significantly less from bronchial asthma,” Frei states. The positive aftereffect of sialic acidity Neu5Gc around the respiratory system system was confirmed utilizing a mouse-model: The Neu5Gc molecules consumed with food improved the lung purpose of the rodents, therefore reducing bronchial asthma signs and symptoms.

From farm effect to allergy prevention

To know the mechanism of methods Neu5Gc affects a persons defense mechanisms, researchers examined various cells from the defense mechanisms that may play a role during a degeneration. By having an interesting result – in the kids tested as well as on your pet model: Connection with Neu5Gc didn’t reduce immunoglobulin E, the antibody that often occurs during allergy symptoms, however it initiates an anti-inflammatory result of the defense mechanisms. “This happens through so-known as regulatory T-cells, that have an elevated presence,” Frei explains. “These T-cells dampen incorrect responses from the defense mechanisms and also have a strong anti-inflammatory effect. Our research results open possibilities for transferring the protective aftereffect of farms to any or all children. In this manner, we are able to possibly lay an essential foundation stone for effective allergy prevention.”

Source:

http://world wide web.media.uzh.ch/en/Press-Releases/2017/Bronchial asthma_Children.html

Anti-bronchial asthma drug shows bloodstream glucose improvement among some patients with diabetes type 2

After 12 days of taking an anti-bronchial asthma drug, a subset of patients with diabetes type 2 demonstrated a clinically significant decrease in bloodstream glucose throughout a randomized, double blind, placebo-controlled medical trial, report College of California North Park Med school and College of Michigan researchers.

Inside a paper publishing This summer 5 in Cell Metabolic process, a group brought by Alan Saltiel, PhD, director from the UC North Park Institute for Diabetes and Metabolic Health, and Elif Dental, MD, director from the MEND Weight problems and Metabolic Disorder Program in the College of Michigan, together with scientists in the Salk Institute for Biological Sciences, identified a molecular signature in patients who taken care of immediately amlexanox, an anti-inflammatory and anti-allergic drug accustomed to treat bronchial asthma which was coded in the 1980s in Japan. The invention is not prepared for the clinic, however it does reveal a possible new therapeutic method for treating diabetes type 2.

“Whenever we checked out the drug-treated group we had a bimodal distribution, that’s, there have been some responders and a few non-responders. We did not realise why, therefore we did a molecular analysis from biopsies of fat cells we required from patients at the start and finish from the study,” stated Saltiel.

“Within the responder group, the amount of inflammation in fat was greater compared to the non-responder group at the outset of the research, indicating that there’s something about inflammation that predisposes someone to respond. And, that which was really amazing was there were greater than 1,100 gene changes that happened solely within the responders.”

Amlexanox is definitely an inhibitor of two enzymes, IKKɛ and TBK1. In the past studies, Saltiel and team had learned that both of these enzymes are caused in obese rodents, creating a stop by energy expenditure or decrease in calories expended. This motivated them to consider inhibitors of those enzymes by screening a library of 150,000 chemicals. They found amlexanox. Giving obese rodents the inhibitor caused them to shed weight, while their sensitivity to insulin elevated, improving their diabetes and fatty liver disease.

A persons trial says gene changes that happened within the mouse model also happened within the human responder group. Bloodstream sugar within the medical trial patients went lower as genes active in the expenditure of one’s altered.

The evidence of concept trial started by having an united nations-blinded safety trial of six patients. It had been adopted with a controlled trial of 42 obese patients with diabetes type 2. Half of the sufferers were randomized to some placebo group as the partner received amlexanox for 3 several weeks. Bloodstream sugar, insulin sensitivity, weight and liver fat were measured. A biopsy of fat cells from each patient’s midsection was taken pre and post the trial to determine alterations in gene expression.

“Probably the most exciting thing about this is we have a brand new drug that has not been studied before,” stated Saltiel. “It is a new mechanism for any diabetes and fatty liver drug. It’s promising, but there are plenty of questions that should be clarified still.”

Included in this: Which gene changes are the most crucial to focus on? What is the right drug dosage? What time if it is administered? How frequently should patients go ahead and take drug? The other drug combinations may be used with amlexanox? Can the proportion of responders be elevated? Will the advantageous results of the drug be sustained for a longer period?

One-third from the participants within the blinded study responded. Among responders with nonalcoholic fatty liver disease, a noticable difference seemed to be seen.

Saltiel stated his lab at UC North Park Med school intends to dive much deeper in to the gene changes to higher understand that are most significant, which affect liver fat, which result in alterations in bloodstream sugar levels and much more. He’s planning for a new human medical trial with colleagues at Michigan.

“We are planning new research to check out whether we are able to stratify patients who will probably respond in line with the amount of underlying inflammation,” stated Saltiel. “Another study will consider a in conjunction with another drug that people think is going to be particularly effective.”

Source:

https://health.ucsd.edu/news/releases/Pages/2017-07-05-repurposed-bronchial asthma-drug-shows-bloodstream-sugar-improvement-among-some-diabetics.aspx

Discovery could impact understanding, management of autoimmune and inflammatory illnesses

Scientists in the Research Institute from the McGill College Health Center (RI-MUHC) might have cracked the code to comprehending the purpose of special cells known as regulatory T Cells. Treg cells, because they are frequently known, control and regulate our defense mechanisms to avoid excessive reactions. The findings, printed in Science Immunology, will have a major impact within our understanding and management of all autoimmune illnesses and many chronic inflammatory illnesses for example joint disease, Crohn’s disease in addition to broader conditions for example bronchial asthma, allergic reactions and cancer.

Researchers chose to make this discovery by investigating an uncommon human mutation inside a gene known as FOXP3. Although the significance of the FOXP3 gene within the proper purpose of Treg cells continues to be extensively recorded, its mechanisms remained as not fully understood by scientists.

“We learned that this mutation within the FOXP3 gene affects the Treg cell’s capability to dampen the immune response, which leads to the defense mechanisms overreacting and causing inflammation,” explains the study’s lead author, Dr. Ciriaco Piccirillo, immunologist and senior researcher within the Infectious Illnesses and Immunity within the Global Health Program in the RI-MUHC, along with a professor of Immunology at McGill College. “This discovery provides for us key insights about how Treg cells are born and how they may be controlled.”

Because of an worldwide collaboration and cutting-edge technology in the Immunophenotyping Platform in the RI-MUHC, they could make their discovery only using a couple of drops of bloodstream from the five-week-old newborn boy who died in ’09 from the rare and frequently fatal inherited genetic immune disorder known as IPEX. Previously 4 decades, less than 200 installments of IPEX happen to be identified worldwide. Over 60 different mutations from the FOXP3 gene are recognized to cause IPEX and thought to lead to non-functional Treg Cells.

“That which was unique relating to this situation of IPEX could be that the patient’s Treg cells were completely functional aside from one crucial element: being able to shut lower the inflammatory response,” states Dr. Piccirillo.

“Understanding this unique mutation has permitted us to reveal the number of milder types of chronic inflammatory illnesses or autoimmune illnesses might be associated with modifications in FOXP3 functions,” adds the study’s first author, Khalid Bin Dhuban, a postdoctoral fellow in Dr. Piccirillo’s laboratory.

From fundamental biology to clinical treatment

Dr. Piccirillo and the colleagues have previously created a molecule that may restore the Treg cells’ capability to control the defense mechanisms for patients with similar rare mutation. The drug continues to be tested in animal models and also the researchers are hopeful they may also develop similar drugs which will make an application for other concerns where Treg cells are recognized to be slightly defective for example joint disease, type I diabetes, ms and lupus.

“Presently, we must shut lower the entire defense mechanisms with aggressive suppressive therapies in a variety of autoimmune and inflammatory illnesses,” explains Dr. Piccirillo. Our goal would be to boost the activity of those Treg cells in a few settings, for example autoimmune illnesses, but you want to transform it lower in other settings, for example cancer. With this particular discovery, we’re going for a big part of the best direction.”

Dr. Ciriaco Piccirillo can also be the director from the Center of Excellence in Translational Immunology (CETI), a recently established research coalition based in the Research Institute from the MUHC that fosters linkages among biomedical investigators and clinicians for interdisciplinary immunology research centered on the understanding and management of immune-based illnesses.

What exactly are Regulatory T Cells?

Treg cells really are a special type of white-colored bloodstream cells or lymphocytes that prevent other immune cells from attacking your body’s own tissues, in addition to controlling immune responses against microbes along with other non-pathogenic agents, for example pollen, dust or benign recommended food groups. It is really an important “self-check” included in the defense mechanisms to avoid excessive reactions.

Source:

http://world wide web.mcgill.ca/newsroom/channels/news/how-couple of-drops-bloodstream-brought-breakthrough-immunology-268832

Stem Cells To Potentially Treat Bronchial asthma

Highlights

  • Caused pluripotent stem cells are a kind of pluripotent stem cell that is able to be differentiated into a number of tissue types.
  • Mesenchymal stem cells (MSCs) produced from caused pluripotent cells can regenerate broken lung tissue.
  • The MSCs reduced inflammation, airway remodeling and airway hyper-responsiveness in bronchial asthma caused rodents.

Bronchial asthma is really a condition where the airways from the lung area become either narrowed or completely blocked, obstructing normal breathing. This obstruction from the lung area, however, is reversible, either spontaneously or with medication.

Structural changes referred to as airway remodeling (AWR) characterize chronic/severe bronchial asthma and lead to lung disorder.

Research brought by scientists at Monash College has proven that the new therapy developed through stem cell technology holds promise like a strategy to chronic bronchial asthma.

Mesenchymal Stem Cells in Bronchial asthma Treatment

The Monash Biomedicine Discovery Institute (BDI) scientists provided the experimental expertise to check Cynata Therapeutics’ caused pluripotent stem cell-derived mesenchymal stem cells (MSCs) inside a type of experimental bronchial asthma.

Caused pluripotent stem cells are a kind of pluripotent stem cell that may be generated from adult cells they be capable of be differentiated into a number of tissue types and, within this situation, MSCs that may regenerate broken lung tissue.

Lead researchers Affiliate Professor Chrishan Samuel and Dr Simon Royce tested the effectiveness from the MSCs on three critical factors of bronchial asthma inside a preclinical type of chronic allergic airways disease: inflammation airway remodeling (structural changes that exist in lung area because of prolonged inflammation) and airway hyperresponsiveness (the clinical characteristic of bronchial asthma).

The research discovered that the MSCs could effectively reduce inflammation, reversed indications of airway remodelling and completely normalised airway/lung fibrosis and airway hyperresponsiveness, specially when delivered intranasally.

It concluded that they’re going to give a novel stand-alone therapy or perhaps an adjunct therapy for categories of bronchial asthma sufferers who don’t react to current (corticosteroid) therapy.

“Most significantly, what we should found was you are able to treat fibrosis (hardening or scarring from the lung) effectively,Inch stated Affiliate Professor Samuel, who heads the Monash BDI’s Fibrosis Laboratory.

“When we have tested other kinds of stem cells they haven’t had the ability to fully reverse scarring and lung disorder connected with bronchial asthma – we have needed to combine all of them with anti-scarring drugs to accomplish this. These cells were outstanding by themselves because they could effectively turn back scarring that includes to lung disorder and difficulty in breathing,” he stated.

Further research is going to be conducted to check the MSCs in conjunction with, or over a clinically-used corticosteroid. Numerous studies while using cells like a novel target for bronchial asthma will be envisaged.

Reference

  1. Samuel, C. S et al., Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness connected with chronic allergic airways disease, FASEB Journal (2017) http://dx.doi.org/10.1096/fj.201700178R.

Source: Medindia

School-Based Treatments are Growing for Bronchial asthma Treatment

For groups of school-aged children, you will find couple of occasions more demanding than mornings, when parents or caregivers want to get kids ready for his or her school day, pack everything they require and obtain them out of the door promptly.

Doctors and scientific study has lengthy known that the amount of stress patients experience is inversely associated with how adherent they’re with taking medications: The greater the strain, the not as likely people are to consider doses of the medication properly, promptly or whatsoever. These demanding mornings, states Stephen J. Educate, M.D., M.P.H., chair from the Department of Pediatrics at Children’s National Health System, can spell danger for kids with persistent bronchial asthma. Bronchial asthma is really a symptom in which your airways narrow and swell and convey extra mucus. This could make breathing difficult and trigger coughing, wheezing and difficulty breathing. This chronic condition is usually given nightly and morning doses of inhaled corticosteroids (ICS), medications that decrease lung inflammation to avoid bronchial asthma attacks. When children miss a morning dose as their people are too busy, their bronchial asthma signs and symptoms can exacerbate, making them miss school, be not able to sign up in pursuits like sports or lose sleep during the night.

‘Asthma affects people of every age group, however it most frequently starts during childhood. Within the U . s . States, greater than 25 million people are recognized to have bronchial asthma.’

But Dr. Educate and colleagues were built with a simple idea to bypass the morning struggle for a lot of families: Rather of attempting to suit delivery of ICS into a previously packed schedule, why don’t you delegate it towards the school nurse?
“We believed that when we might have individuals morning doses administered by these medically trained people with great technique and regularity, maybe we’d see some improved outcomes in kids,” Dr. Educate states. “So we did, inside a striking way.”

Dr. Educate and colleagues employed 46 children to sign up inside a pilot study, printed online June 21, 2017 within the Journal of Bronchial asthma. To become qualified, these participants needed to be in grades school through eighth within the Washington, D.C. public school system as well as on State medicaid programs, demonstrating the kind of financial need that may increase the cumulative stress a household already faces. The kids were scattered across 18 schools.

Twenty-one of these simple participants received morning doses of ICS (the intervention group), that the researchers presented to school nurses with an bronchial asthma plan of action. The remainder (the control group) continued to be on their own prescribed evening and morning doses in your own home.

After two months, they adopted track of schools and families. Through electronic records stored by each school, they discovered that the intervention group received greater than 90 % of the prescribed morning doses–comparable number as reported by parents from the control group. However, the 2 groups shown impressive variations in quality-of-existence measures:

While about 24 percent from the intervention group missed one or less times of school because of bronchial asthma throughout the 60-day trial, about 44 % from the control group did.

About 43 percent from the intervention group reported functional limitations because of their bronchial asthma, in contrast to 74 percent from the control group.

The intervention group reported only one.7 nights with bronchial asthma-related sleep loss in the last two days, in contrast to 4.1 nights within the control group.

Furthermore, no more than one-quarter from the intervention group needed adjustments in family existence to support their bronchial asthma, compared using more than one-1 / 2 of the control group.

The reason why of these variations aren’t obvious, states Dr. Educate. But he and colleagues claim that they could be because of over-reporting of the number of doses were delivered in your own home within the control group or improper administration of those drugs in your own home.

Regardless, he states, the outcomes reveal that this kind of school-based intervention wasn’t only achievable for kids, school nurses and families, but additionally brought to several positive health outcomes for that participants who received it. In line with the outcomes of this research, Dr. Educate and colleagues have began to prescribe school-based administration of morning ICS doses to families thinking about receiving them like a new standard of care.

“These data, coupled with data from similar studies at other institutions, claim that school-based treatments are more and more being a very real and proven choice for clinicians and families when adherence is really a struggle,” he states.

Source: Eurekalert

Activation from the mTOR signaling path is needed for bronchial asthma onset


Ethics statement

All methods were transported in compliance with relevant guidelines and rules. All experiment protocols were approved with a named institutional and/or licensing committee. Particularly, for that patient study, all experiment protocols were reviewed and authorized by the Medical Ethics Association from the Third Affiliated Hospital of Zhengzhou College, and written informed consents were caused by the mother and father of children involved for animal studies, all protocols were reviewed and authorized by the Animal Ethics Committees from the Third Affiliated Hospital of Zhengzhou College under College Animal Research Guideline 1996–21. Creatures were housed and treated underneath the approved protocols, and all sorts of efforts were created to reduce animal suffering.

Clinical study

The patients were categorized into four groups: an bronchial asthma attack group, bronchial asthma remission group, community-acquired pneumonia group, and normal healthy group. The bronchial asthma group contained 34 children (17 males, 17 females), aged 4.2-10.8 years (mean = 6.5 ± 2.1 years), with bronchial asthma who’d visited a physician or were hospitalized within the Third Affiliated Hospital of Zhengzhou College from The month of january 2014 to June 2014. Patients were sampled within 24 hours of first experiencing elevated signs and symptoms once they visited the physician or were hospitalized. Bronchial asthma attack patient were treatment with steroid budenoside after sampling. The remission group incorporated 35 children (18 males, 17 females), aged 3.eight to ten.24 months (mean = 6.4 ± 1.8 years), who’d experienced an bronchial asthma attack after which were in bronchial asthma remission through either treatment using the steroid budenoside and β2-adrenergic receptor agonists (Terbutaline Sulphate Solution for Nebulization, 10 males and 9 females) or self-remission with no treatment (8 males and eight females). Patients were sampled within 24 hours of entering remission. There have been no record significances between patients within the remission group without or with treatment in serum mTOR, Th17, Treg, IL-17, TGF-β, IL-10, IL-4, and IFN-γ (Supplemental Table 1). All the patients with bronchial asthma were confirmed as cases based on the printed diagnostic standard41. The pneumonia group comprised 37 children (20 males, 17 females), aged 3.7 to 9.nine years (mean = 6.5 ± 1.nine years), who have been identified as having pneumonia within the same hospital within the same period because the patients with bronchial asthma. All the patients with pneumonia were confirmed as cases based on the printed diagnostic standard41. The healthy control group comprised 31 normal healthy children (17 males, 14 females), aged 2.9 to 9.three years (mean = 5.9 ± 1.four years), which were at random selected from individuals who’d an actual examination within the hospital within the same period because the patients with bronchial asthma and pneumonia. There have been no statistically significant variations in ages and gender composition one of the groups (p > 0.05).

Animal study

60 specific virus-free (SPF) grade 6- to eight-week-old female Balb/C rodents were supplied by the Zhengzhou College Animal Experiment Center (serial number: SCXK[Yu] 2015–0005) and housed within the Experiment Core Third Affiliated Hospital of Zhengzhou College with free use of water and food for just one week just before initiation from the experiment. Mean mouse body weights were 20 ± 2 g as based on an electronic scale prior to the experiment. Rodents were split into six groups: saline control (A), OVA-caused asthmatic rodents (B), asthmatic rodents given budesonide (C), asthmatic rodents given the mTOR inhibitor rapamycin (D), asthmatic rodents given the PI3K inhibitor LY294002 (E), and asthmatic rodents given the Akt inhibitor triciribine (F). The bronchial asthma mouse model started with different previous study42 with modifications. Briefly, each mouse was injected intraperitoneally with .2 mL OVA (Sigma)/aluminum hydroxide on days 1, 8, and 15, after which exposed to twoPercent OVA inhalation for 30 minutes for stimulation every second day, beginning from day 22 for as many as 10 doses. Bronchial asthma started within the treatment groups utilizing the same procedure, except by having an additional 30 minutes of inhalation treatment with 1 mg (2 mL) budesonide (C) or intraperitoneal injection of rapamycin (D, 3 mg/kg, Sigma), LY294002 (E, 1 mg/kg, Sigma), or triciribine (F, 1 mg/kg, Sigma) before stimulation. Rapamycin, LY294002, and triciribine were dissolved in dimethyl sulfoxide (DMSO) to produce a stock solution which was diluted with sterile phosphate-buffered saline (PBS) before use. Negative control rodents were treated underneath the same protocol as asthmatic rodents, with the exception that OVA was substituted for saline solution. No rodents from the six groups died throughout the experiments.

Look at OVA-caused murine type of bronchial asthma

Rodents were split into an bronchial asthma group and control group. There have been no statistically significant variations between both of these groups in body weights, activity levels, or response to stimuli prior to the experiment. No swellings or ulcers were observed during or following the intraperitoneal injection. 72 hours into stimulation, rodents within the asthmatic group displayed trouble sleeping, sneezing, and deepened breathing, which stopped about 10 minutes after finishing the 30 minutes of OVA stimulation. 5 days into OVA stimulation, rodents within the bronchial asthma group shown either hypomania or perhaps a significant decrease in activity levels. Rodents within the control group socialized because they did prior to the experiment, exhibiting healthy appetites, agile movements, and glossy fur. Rodents that displayed shortened breath, trouble sleeping, cyanosis, salivation, in addition to fecal and urine incontinence, after inhalation from the allergen indicated the effective establishment from the bronchial asthma mouse model. More serious reactions incorporated hypopnea or respiratory system arrhythmia, respiratory system failure, and lethargic. All rodents were evaluated by H&E, IHC, and PAS staining for asthmatic markers for example inflammatory cells, thickening of airway smooth muscles, airway walls, and epithelial mucosa.

BALF cell collection

Rodents were anesthetized and stabilized on the wooden board 24 hours following the last stimulation, as well as their chests were opened up for an additional procedures. The distal trachea and left primary bronchus were ligated, after which each mouse was tracheally intubated having a modified 22 G catheter for any .5-mL cold PBS lavage performed three occasions. BALF was collected having a recycle rate of >85%. Supernatants were collected after 10 minutes of centrifugation at 4 °C and 1500 rpm, and were stored at −20 °C to be used in experiments.

Isolation of sera from humans and rodents

Fasting venous bloodstream was collected from patients with bronchial asthma and from controls, permitted to clot at 70 degrees, and centrifuged for 10 minutes at 2000 rpm. Serum was collected in the top layer within the tube, and aliquoted to be used in experiments. Mouse bloodstream was collected by sterile retro-orbital bleeding and processed similarly.

Enzyme-linked immunosorbent assay (ELISA)

ELISA was performed on clinical serum samples, mouse sera, and BALF based on the manufacturer’s instructions. ELISA kits used were the next: Human mTOR ELISA Recognition Package, Human IL-17 ELISA Recognition Package, Human IL-10 ELISA Recognition Package, Human IL-4 ELISA Recognition Package, Human IFN-γ ELISA Recognition Package, Human TGF-β ELISA Recognition Package, Mouse mTOR ELISA Recognition Package, Mouse IL-17 ELISA Recognition Package, Mouse TGF-β ELISA Recognition Package, Mouse IL-10 ELISA Recognition Package, Mouse IL-4 ELISA Recognition Package, and Mouse IFN-γ ELISA Recognition Package, all from R&D Systems.

Flow cytometry

PBMCs were suspended in a power of 1 × 106/mL in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum. To activate cells, PMA + Ion (25 ng/mL + 1 mg/mL) and protein transport inhibitor BFA (1 mg/mL) (both from Sigma) were added, and cells were incubated at 37 °C for 5 hours with 5% CO2. The activated cells were stained with FITC-labeled anti-human CD3 and PerCP-labeled anti-human CD8 after which stored at nighttime at 4 °C for 20 min. After being washed with PBS, cells were fixed with 100 mL fixation solution for 15 minutes after which washed again. Permeabilization working solution was added, mixed for 15 minutes, after which washed with PBS. Intracellular staining was performed with the help of APC-labeled anti-human IL-17, and, concurrently, homeotype control reaction tubes were prepared. After pre-cooling and washing with PBS, cells were counted by FACSCalibur flow cytometry (BD Biosciences). The outcomes were examined by CellQuest software, with CD3+CD8IL-17+ representing Th17 cells.

PBMC suspensions without stimulation were supplemented with human FITC-labeled anti-human CD4, APC-labeled anti-human CD25, and PE-labeled anti-human CD127, and incubated at nighttime at 70 degrees for 15 minutes. Cells were washed with PBS two times, after which fixed with 300 μL PBS. Cells were detected by flow cytometry (FACSCalibur, BD Biosciences) and examined by CellQuest software, with CD4+CD25high+CD127low representing Treg cells43.

H&E, PAS, and IHC staining

The procedures were performed based on the package manufacturer instructions. For H&E staining to identify inflammatory cells, the amount of eosinophils, neutrophils, and lymphocytes were averaged from five different areas on every slide were evaluated microscopically at 400× magnification. IHC staining was scored through the same investigator underneath the same microscope, with yellow or brown staining considered positive signals. Mouse lung tissues were stained with p-PI3K, p-Akt, p-mTOR, and p-p70S6k antibodies and yellow/brown staining was scored underneath the microscope. Images were acquired at 200 × magnification, five positive areas per slice were selected for analysis, and optical density values were measured. The concentration of H&E, IHC, and PAS staining was evaluated semi-quantitatively while using following groups: (no staining), 1+ (weak but detectable staining), 2+ (moderate or distinct staining), and three+ (intense staining). For every specimen, an HSCORE value was derived by calculating the sum percentages of cells which were stained in every intensity category and multiplying that value through the weighted concentration of the staining, while using formula HSCORE = Pi (i + 1), where i represents the intensity score, and Pi may be the corresponding number of cells44. In every slide, five different areas and 100 cells per area were evaluated microscopically with α*40 objective magnification. The proportion of cells each and every intensity in those areas was resolute at different occasions by two investigators blinded towards the supply of the samples, and also the average of the scores was utilized.

Western blot

Lung tissue from each mouse was sampled three occasions and eager for western blot. The lung tissues were lysed in protein lysis buffer, and proteins were extracted and quantified by Coomassie blue staining. Proteins were detected by western blot using antibodies against p-PI3K (Cell Signaling Technology), p-Akt (Cell Signaling Technology), p-mTOR (Santa Cruz Biotechnology), and p-p70S6k (Epitomics). Proteins were quantified using Journey software 3. and normalized against β-actin being an internal control.

Record analysis

All data were examined with SPSS v21. and were presented as mean ± standard deviation (SD). Each group of data was resolute to adapt to some normal distribution, examined by F-test for homogeneity of variance, after which exposed to some univariate analysis between groups inside a multi-application, pairwise comparison with Bonferroni correction. Correlations were based on Pearson correlation, with α = 0.05 set because the qualifying criterion for record significance.

Therapeutic vaccines for allergic disease

  • 1.

    Kristiansen, M. et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatr. Allergy Immunol. 28, 18–29 (2017).

  • 2.

    Elenius, V. & Jartti, T. Vaccines: could asthma in young children be a preventable disease?‬‬‬‬‬‬‬. Pediatr. Allergy Immunol. 27, 682–686 (2016).

  • 3.

    Hankin, C. S., Cox, L., Bronstone, A. & Wang, Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. J. Allergy Clin. Immunol. 131, 1084–1091 (2013).

  • 4.

    Hankin, C. S. et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann. Allergy Asthma Immunol. 104, 79–85 (2010).

  • 5.

    Noon, L. Prophylactic inoculation against hay fever. Lancet 177, 1572–1573 (1911).

  • 6.

    Frankland, A. W. & Augustin, R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet 263, 1055–1057 (1954).

  • 7.

    Johnstone, D. E. & Dutton, A. The value of hyposensitization therapy for bronchial asthma in children—a 14-year study. Pediatrics 42, 793–802 (1968).

  • 8.

    Jacobsen, L. et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62, 943–948 (2007).

  • 9.

    Wan, H. et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J. Clin. Invest. 104, 123–133 (1999).

  • 10.

    Wan, H. et al. Quantitative structural and biochemical analyses of tight junction dynamics following exposure of epithelial cells to house dust mite allergen Der p 1. Clin. Exp. Allergy 30, 685–698 (2000).

  • 11.

    Wan, H. et al. The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. Clin. Exp. Allergy 31, 279–294 (2001).

  • 12.

    Gutowska-Owsiak, D. et al. The histamine-synthesizing enzyme histidine decarboxylase is upregulated by keratinocytes in atopic skin. Br. J. Dermatol. 171, 771–778 (2014).

  • 13.

    Kim, J. H. et al. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J. Allergy Clin. Immunol. 136, 205–208.e209 (2015)

  • 14.

    Kempkes, C., Buddenkotte, J., Cevikbas, F., Buhl, T. & Steinhoff, M. in Itch: Mechanisms and Treatment (eds Carstens, E. & Akiyama, T.) (CRC Press, 2014).

  • 15.

    Boltjes, A. & Van Wijk, F. Human dendritic cell functional specialization in steady-state and inflammation. Front. Immunol. 5, 131 (2014).

  • 16.

    Jarrett, R. et al. Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite-derived phospholipase. Sci. Transl. Med. 8, 325ra318 (2016).

  • 17.

    McAleer, M. A. & Irvine, A. D. The multifunctional role of filaggrin in allergic skin disease. J. Allergy Clin. Immunol. 131, 280–291 (2013).

  • 18.

    Lack, G. Epidemiologic risks for food allergy. J. Allergy Clin. Immunol. 121, 1331–1336 (2008).

  • 19.

    Divekar, R. & Kita, H. Recent advances in epithelium-derived cytokines (IL-33, IL-25 and TSLP) and allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 15, 98–103 (2015).

  • 20.

    Vroling, A. B., Duinsbergen, D., Fokkens, W. J. & van Drunen, C. M. Allergen induced gene expression of airway epithelial cells shows a possible role for TNF-alpha. Allergy 62, 1310–1319 (2007).

  • 21.

    Gutowska-Owsiak, D. & Ogg, G. S. The epidermis as an adjuvant. J. Invest. Dermatol. 132, 940–948 (2012).

  • 22.

    Harris, H. E., Andersson, U. & Pisetsky, D. S. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 8, 195–202 (2012).

  • 23.

    Shim, E. J. et al. The role of high-mobility group box-1 (HMGB1) in the pathogenesis of asthma. Clin. Exp. Allergy 42, 958–965 (2012).

  • 24.

    Karuppagounder, V. et al. Resveratrol attenuates HMGB1 signaling and inflammation in house dust mite-induced atopic dermatitis in mice. Int. Immunopharmacol. 23, 617–623 (2014).

  • 25.

    Soumelis, V. et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3, 673–680 (2002).

  • 26.

    Salimi, M. et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J. Exp. Med. 210, 2939–2950 (2013).

  • 27.

    Salimi, M. et al. Group 2 innate lymphoid cells express functional NKp30 receptor inducing type 2 cytokine production. J. Immunol. 196, 45–54 (2016).

  • 28.

    Simons, B. et al. PGI2 controls pulmonary NK cells that prevent airway sensitization to house dust mite allergen. J. Immunol. 198, 461–471 (2017).

  • 29.

    Han, N. R. et al. TSLP induces mast cell development and aggravates allergic reactions through the activation of MDM2 and STAT6. J. Invest. Dermatol. 134, 2521–2530 (2014).

  • 30.

    Hosoki, K., Itazawa, T., Boldogh, I. & Sur, S. Neutrophil recruitment by allergens contribute to allergic sensitization and allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 16, 45–50 (2016).

  • 31.

    Ferreira, M. A. Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies. Mediators Inflamm. 12, 259–267 (2003).

  • 32.

    Barker, J. N. et al. Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am. J. Pathol. 139, 869–876 (1991).

  • 33.

    Kato, T., Takai, T., Mitsuishi, K., Okumura, K. & Ogawa, H. Cystatin A inhibits IL-8 production by keratinocytes stimulated with Der p 1 and Der f 1: biochemical skin barrier against mite cysteine proteases. J. Allergy Clin. Immunol. 116, 169–176 (2005).

  • 34.

    Ventura, I. et al. Neutrophils from allergic asthmatic patients produce and release metalloproteinase-9 upon direct exposure to allergens. Allergy 69, 898–905 (2014).

  • 35.

    Voynow, J. A. et al. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am. J. Physiol. 276, L835–L843 (1999).

  • 36.

    Lefrancais, E. et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc. Natl. Acad. Sci. U. S. A. 109, 1673–1678 (2012).

  • 37.

    Bourgeois, E. A. et al. Bee venom processes human skin lipids for presentation by CD1a. J. Exp. Med. 212, 149–163 (2015).

  • 38.

    Subramaniam, S. et al. Elevated and cross-responsive CD1a-reactive T cells in bee and wasp venom allergic individuals. Eur. J. Immunol. 46, 242–252 (2016).

  • 39.

    Reyes, N. J., Mayhew, E., Chen, P. W. & Niederkorn, J. Y. NKT cells are necessary for maximal expression of allergic conjunctivitis1. Int. Immunol. 22, 627–636 (2010).

  • 40.

    Wingender, G. et al. Invariant NKT cells are required for airway inflammation induced by environmental antigens. J. Exp. Med. 208, 1151–1162 (2011).

  • 41.

    Akbari, O. et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9, 582–588 (2003).

  • 42.

    Schouten, B. et al. Invariant natural killer T cells contribute to the allergic response in cow’s milk protein-sensitized mice. Int. Arch. Allergy Immunol. 159, 51–59 (2012).

  • 43.

    Korsgren, M. et al. Natural killer cells determine development of allergen-induced eosinophilic airway inflammation in mice. J. Exp. Med. 189, 553–562 (1999).

  • 44.

    Ple, C. et al. Natural killer cells accumulate in lung-draining lymph nodes and regulate airway eosinophilia in a murine model of asthma. Scand. J. Immunol. 72, 118–127 (2010).

  • 45.

    Seneviratne, S. L. et al. Allergen-specific CD8(+) T cells and atopic disease. J. Clin. Invest. 110, 1283–1291 (2002).

  • 46.

    Harris, S. J. et al. Prediction of murine MHC class I epitopes in a major house dust mite allergen and induction of T1-type CD8+T cell responses. Int. Immunol. 9, 273–280 (1997).

  • 47.

    Lian, J. & Luster, A. D. Chemokine-guided cell positioning in the lymph node orchestrates the generation of adaptive immune responses. Curr. Opin. Cell Biol. 36, 1–6 (2015).

  • 48.

    Jutel, M. & Akdis, C. A. T-cell subset regulation in atopy. Curr. Allergy Asthma Rep. 11, 139–145 (2011).

  • 49.

    Tang, Y. et al. Antigen-specific effector CD8 T cells regulate allergic responses via IFN-gamma and dendritic cell function. J. Allergy Clin. Immunol. 129, 1611–1620 (2012). e1614.

  • 50.

    Russano, A. M. et al. Recognition of pollen-derived phosphatidyl-ethanolamine by human CD1d-restricted gamma delta T cells. J. Allergy Clin. Immunol. 117, 1178–1184 (2006).

  • 51.

    Jyonouchi, S. et al. Invariant natural killer T cells from food allergic versus non-allergic children exhibit differential responsiveness to milk-derived sphingomyelin. J. Allergy Clin. Immunol. 128, 102–109 (2011). e113.

  • 52.

    Agea, E. et al. Human CD1-restricted T cell recognition of lipids from pollens. J. Exp. Med. 202, 295–308 (2005).

  • 53.

    Mondot, S., Boudinot, P. & Lantz, O. MAIT, MR1, microbes and riboflavin: a paradigm for the co-evolution of invariant TCRs and restricting MHCI-like molecules? Immunogenetics 68, 537–548 (2016).

  • 54.

    Kjer-Nielsen, L. et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717–723 (2012).

  • 55.

    Treiner, E. et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422, 164–169 (2003).

  • 56.

    Van Rhijn, I. et al. A conserved human T cell population targets mycobacterial antigens presented by CD1b. Nat. Immunol. 14, 706–713 (2013).

  • 57.

    Burton, O. T. et al. Direct effects of IL-4 on mast cells drive their intestinal expansion and increase susceptibility to anaphylaxis in a murine model of food allergy. Mucosal Immunol. 6, 740–750 (2013).

  • 58.

    Nakamura, Y. et al. Factors that stimulate the proliferation and survival of eosinophils in eosinophilic pleural effusion: relationship to granulocyte/macrophage colony-stimulating factor, interleukin-5, and interleukin-3. Am. J. Respir. Cell Mol. Biol. 8, 605–611 (1993).

  • 59.

    Kimura, M., Tsuruta, S. & Yoshida, T. Correlation of house dust mite-specific lymphocyte proliferation with IL-5 production, eosinophilia, and the severity of symptoms in infants with atopic dermatitis. J. Allergy Clin. Immunol. 101, 84–89 (1998).

  • 60.

    Yang, M. et al. Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-alpha chain and STAT-6 independently of IL-5 and eotaxin. Am. J. Respir. Cell Mol. Biol. 25, 522–530 (2001).

  • 61.

    Voehringer, D. Basophil modulation by cytokine instruction. Eur. J. Immunol. 42, 2544–2550 (2012).

  • 62.

    Gordon, S. & Martinez, F. O. Alternative activation of macrophages: mechanism and functions. Immunity 32, 593–604 (2010).

  • 63.

    Anthony, R. M. et al. Memory T(H)2 cells induce alternatively activated macrophages to mediate protection against nematode parasites. Nat. Med. 12, 955–960 (2006).

  • 64.

    Arango Duque, G. & Descoteaux, A. Macrophage cytokines: involvement in immunity and infectious diseases. Front. Immunol. 5, 491 (2014).

  • 65.

    Joerink, M., Savelkoul, H. F. & Wiegertjes, G. F. Evolutionary conservation of alternative activation of macrophages: structural and functional characterization of arginase 1 and 2 in carp (Cyprinus carpio L.). Mol. Immunol. 43, 1116–1128 (2006).

  • 66.

    Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896 (2010).

  • 67.

    Huang, L.-R., Chen, F.-L., Chen, Y.-T., Lin, Y.-M. & Kung, J. T. Potent induction of long-term CD8(+) T cell memory by short-term IL-4 exposure during T cell receptor stimulation. Proc. Natl. Acad. Sci. U. S. A. 97, 3406–3411 (2000).

  • 68.

    Milovanovic, M., Drozdenko, G., Weise, C., Babina, M. & Worm, M. Interleukin-17A promotes IgE production in human B cells. J. Invest. Dermatol. 130, 2621–2628 (2010).

  • 69.

    Moon, T. C., Befus, A. D. & Kulka, M. Mast cell mediators: their differential release and the secretory pathways involved. Front. Immunol. 5, 569 (2014).

  • 70.

    Stone, K. D., Prussin, C. & Metcalfe, D. D. IgE, mast cells, basophils, and eosinophils. J. Allergy Clin. Immunol. 125, S73–S80 (2010).

  • 71.

    Stingl, G. & Maurer, D. IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Int. Arch. Allergy Immunol. 113, 24–29 (1997).

  • 72.

    Selb, R. et al. CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells. J. Allergy Clin. Immunol. 139, 290–299 (2017). e294.

  • 73.

    Westman, S., Gustavsson, S. & Heyman, B. Early expansion of secondary B cells after primary immunization with antigen complexed with IgE. Scand. J. Immunol. 46, 10–15 (1997).

  • 74.

    Gustavsson, S., Hjulstrom, S., Liu, T. & Heyman, B. CD23/IgE-mediated regulation of the specific antibody response in vivo. J. Immunol. 152, 4793–4800 (1994).

  • 75.

    Maezawa, Y. et al. IgE-dependent enhancement of Th2 cell-mediated allergic inflammation in the airways. Clin. Exp. Immunol. 135, 12–18 (2004).

  • 76.

    Ceponis, P. J., Botelho, F., Richards, C. D. & McKay, D. M. Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement. J. Biol. Chem. 275, 29132–29137 (2000).

  • 77.

    Gutowska-Owsiak, D. et al. Histamine exerts multiple effects on expression of genes associated with epidermal barrier function. J. Invest. Allergy Clin. Immunol. 24, 231–239 (2014).

  • 78.

    Gutowska-Owsiak, D. et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp. Dermatol. 21, 104–110 (2012).

  • 79.

    Gutowska-Owsiak, D., Schaupp, A. L., Salimi, M., Taylor, S. & Ogg, G. S. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br. J. Dermatol. 165, 492–498 (2011).

  • 80.

    Gutowska-Owsiak, D. & Ogg, G. S. Cytokine regulation of the epidermal barrier. Clin. Exp. Allergy 43, 586–598 (2013).

  • 81.

    Gschwandtner, M. et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 68, 37–47 (2013).

  • 82.

    Howell, M. D. et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin. Immunol. 121, 332–338 (2006).

  • 83.

    Al-Sadi, R., Boivin, M. & Ma, T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front. Biosci. 14, 2765–2778 (2009).

  • 84.

    Leach, L., Eaton, B. M., Westcott, E. D. & Firth, J. A. Effect of histamine on endothelial permeability and structure and adhesion molecules of the paracellular junctions of perfused human placental microvessels. Microvasc. Res. 50, 323–337 (1995).

  • 85.

    Walsh, S. V., Hopkins, A. M. & Nusrat, A. Modulation of tight junction structure and function by cytokines. Adv. Drug Deliv. Rev. 41, 303–313 (2000).

  • 86.

    Ahdieh, M., Vandenbos, T. & Youakim, A. Lung epithelial barrier function and wound healing are decreased by IL-4 and IL-13 and enhanced by IFN-gamma. Am. J. Physiol. Cell Physiol. 281, C2029–C2038 (2001).

  • 87.

    Hirase, T. et al. Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms. J. Biol. Chem. 276, 10423–10431 (2001).

  • 88.

    Zabner, J. et al. Histamine alters E-cadherin cell adhesion to increase human airway epithelial permeability. J. Appl. Physiol. 95, 394–401 (2003).

  • 89.

    Heller, F. et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550–564 (2005).

  • 90.

    Bogiatzi, S. I. et al. Cutting edge: proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes. J. Immunol. 178, 3373–3377 (2007).

  • 91.

    Kubo, A., Nagao, K. & Amagai, M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J. Clin. Invest. 122, 440–447 (2012).

  • 92.

    Albanesi, C. et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J. Immunol. 179, 984–992 (2007).

  • 93.

    Ong, P. Y., Ohtake, T. & Brandt, C. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347, 1151–1160 (2002).

  • 94.

    Dabbagh, K. et al. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J. Immunol. 162, 6233–6237 (1999).

  • 95.

    Atherton, H. C., Jones, G. & Danahay, H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am. J. Physiol. Lung Cell Mol. Physiol. 285, L730–L739 (2003).

  • 96.

    Amrani, Y., Chen, H. & Panettieri, R. A. Jr. Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma? Respir. Res. 1, 49–53 (2000).

  • 97.

    Amrani, Y., Krymskaya, V., Maki, C. & Panettieri, R. A. Jr. Mechanisms underlying TNF-alpha effects on agonist-mediated calcium homeostasis in human airway smooth muscle cells. Am. J. Physiol. 273, L1020–L1028 (1997).

  • 98.

    Tliba, O. et al. IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle. Br. J. Pharmacol. 140, 1159–1162 (2003).

  • 99.

    Nelson, H. S. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J. Allergy Clin. Immunol. Pract. 2, 144–149 (2014). quiz 150-141.

  • 100.

    Aasbjerg, K. et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin. Exp. Allergy 44, 417–428 (2014).

  • 101.

    Schulten, V. et al. Distinct modulation of allergic T cell responses by subcutaneous vs. sublingual allergen-specific immunotherapy. Clin. Exp. Allergy 46, 439–448 (2016).

  • 102.

    Upadhyay, J., Upadhyay, R. B., Agrawal, P., Jaitley, S. & Shekhar, R. Langerhans cells and their role in oral mucosal diseases. N. Am. J. Med. Sci. 5, 505–514 (2013).

  • 103.

    Hovav, A. H. Dendritic cells of the oral mucosa. Mucosal Immunol. 7, 27–37 (2014).

  • 104.

    Seneschal, J. et al. Human epidermal langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 36, 873–884 (2012).

  • 105.

    Till, S. J. et al. Recruitment of CD1a+ Langerhans cells to the nasal mucosa in seasonal allergic rhinitis and effects of topical corticosteroid therapy. Allergy 56, 126–131 (2001).

  • 106.

    Du Toit, G. et al. Identifying infants at high risk of peanut allergy: the Learning Early about Peanut Allergy (LEAP) screening study. J. Allergy Clin. Immunol. 131, 135–143 (2013). e131-e112.

  • 107.

    Du Toit, G. et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N. Engl. J. Med. 372, 803–813 (2015).

  • 108.

    Anagnostou, K. et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 383, 1297–1304 (2014).

  • 109.

    Cui, Z. H., Radinger, M., Sjostrand, M. & Lotvall, J. Repeated allergen exposure reduce early phase airway response and leukotriene release despite upregulation of 5-lipoxygenase pathways. Clin. Transl. Allergy 2, 7 (2012).

  • 110.

    Van Hove, C. L., Maes, T., Joos, G. F. & Tournoy, K. G. Prolonged inhaled allergen exposure can induce persistent tolerance. Am. J. Respir. Cell Mol. Biol. 36, 573–584 (2007).

  • 111.

    Hourihane, J. O. B., Roberts, S. A. & Warner, J. O. Resolution of peanut allergy: case-control study. Br. Med. J. 316, 1271–1275 (1998).

  • 112.

    Nowak-Węgrzyn, A. What makes children outgrow food allergy? Clin. Exp. Allergy 45, 1618–1620 (2015).

  • 113.

    Qamar, N. et al. Naturally occurring tolerance acquisition to foods in previously allergic children is characterized by antigen specificity and associated with increased subsets of regulatory T cells. Clin. Exp. Allergy 45, 1663–1672 (2015).

  • 114.

    Ponce, M., Diesner, S. C., Szépfalusi, Z. & Eiwegger, T. Markers of tolerance development to food allergens. Allergy 71, 1393–1404 (2016).

  • 115.

    Arts, J. H., Mommers, C. & de Heer, C. Dose-response relationships and threshold levels in skin and respiratory allergy. Crit. Rev. Toxicol. 36, 219–251 (2006).

  • 116.

    Arts, J. H. E. & Frieke Kuper, C. Approaches to induce and elicit respiratory allergy: impact of route and intensity of exposure. Toxicol. Lett. 140–141, 213–222 (2003).

  • 117.

    Friedmann, P. S. The relationships between exposure dose and response in induction and elicitation of contact hypersensitivity in humans. Br. J. Dermatol. 157, 1093–1102 (2007).

  • 118.

    Robinson, M. K. et al. The importance of exposure estimation in the assessment of skin sensitization risk. Contact Dermatitis 42, 251–259 (2000).

  • 119.

    Taylor, S. L. et al. Threshold dose for peanut: risk characterization based upon diagnostic oral challenge of a series of 286 peanut-allergic individuals. Food Chem. Toxicol. 48, 814–819 (2010).

  • 120.

    Chung, Y. J. et al. Dose-dependent allergic responses to an extract of Penicillium chrysogenum in BALB/c mice. Toxicology 209, 77–89 (2005).

  • 121.

    Arts, J. H. E., de Koning, M. W., Bloksma, N. & Kuper, C. F. Respiratory allergy to trimellitic anhydride in rats: concentration-response relationships during elicitation. Inhal. Toxicol. 16, 259–269 (2004).

  • 122.

    Novak, N. et al. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. J. Allergy Clin. Immunol. 130, 1153–1158 (2012). e1152.

  • 123.

    Sancho-Serra, Md. C., Simarro, M. & Castells, M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization. Eur. J. Immunol. 41, 1004–1013 (2011).

  • 124.

    Bin Dhuban, K. & Piccirillo, C. A. The immunological and genetic basis of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Curr. Opin. Allergy Clin. Immunol. 15, 525–532 (2015).

  • 125.

    d’Hennezel, E., Bin Dhuban, K., Torgerson, T. & Piccirillo, C. A. The immunogenetics of immune dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. 49, 291–302 (2012).

  • 126.

    Torgerson, T. R. et al. Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. Gastroenterology 132, 1705–1717 (2007).

  • 127.

    Halabi-Tawil, M. et al. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br. J. Dermatol. 160, 645–651 (2009).

  • 128.

    Collison, L. W. et al. Interleukin-35-mediated induction of a novel regulatory T cell population. Nat. Immunol. 11, 1093–1101 (2010).

  • 129.

    Kappen, J. H., Durham, S. R., Veen, H. I. & Shamji, M. H. Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. Ther. Adv. Respir. Dis. 11, 73–86 (2017).

  • 130.

    Jutel, M. et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33, 1205–1214 (2003).

  • 131.

    Fu, C.-L., Ye, Y.-L., Lee, Y.-L. & Chiang, B.-L. Both allergen-specific CD4 and CD8 Type 2 T cells decreased in asthmatic children with immunotherapy. Pediatr. Allergy Immunol. 14, 284–291 (2003).

  • 132.

    Caridade, M., Graca, L. & Ribeiro, R. Mechanisms underlying CD4+Treg immune regulation in the adult: from experiments to models. Front. Immunol. 4, 378 (2013).

  • 133.

    Saxena, A. et al. Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 74, 27–34 (2015).

  • 134.

    Ng, T. H. S. et al. Regulation of adaptive immunity; the role of interleukin-10. Front. Immunol. 4, 129 (2013).

  • 135.

    Varney, V. A. et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. 92, 644–651 (1993).

  • 136.

    Bellinghausen, I. et al. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur. J. Immunol. 27, 1131–1139 (1997).

  • 137.

    McHugh, S. M., Deighton, J., Stewart, A. G., Lachmann, P. J. & Ewan, P. W. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin. Exp. Allergy 25, 828–838 (1995).

  • 138.

    Jutel, M. et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J. Immunol. 154, 4187–4194 (1995).

  • 139.

    Maggi, E. T cell responses induced by allergen-specific immunotherapy. Clin. Exp. Immunol. 161, 10–18 (2010).

  • 140.

    Ryan, J. F. et al. Successful immunotherapy induces previously unidentified allergen-specific CD4+T-cell subsets. Proc. Natl. Acad. Sci. U. S. A. 113, E1286–E1295 (2016).

  • 141.

    Gardner, L. M., O’Hehir, R. E. & Rolland, J. M. High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN-gamma+T cells, apoptosis of CD4+IL-4+T cells and T cell anergy. Int. Arch. Allergy Immunol. 133, 1–13 (2004).

  • 142.

    Wambre, E. et al. Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner. J. Allergy Clin. Immunol. 133, 872–879 (2014). e877.

  • 143.

    Murthy, P. K., Dennis, V. A., Lasater, B. L. & Philipp, M. T. Interleukin-10 modulates proinflammatory cytokines in the human monocytic cell line THP-1 stimulated with Borrelia burgdorferi lipoproteins. Infect. Immun. 68, 6663–6669 (2000).

  • 144.

    Onishi, Y., Fehervari, Z., Yamaguchi, T. & Sakaguchi, S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. 105, 10113–10118 (2008).

  • 145.

    Sojka, D. K., Hughson, A., Sukiennicki, T. L. & Fowell, D. J. Early kinetic window of target T cell susceptibility to CD25+ regulatory T cell activity. J. Immunol. 175, 7274–7280 (2005).

  • 146.

    Bopp, T. et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 204, 1303–1310 (2007).

  • 147.

    Murakami, Y. et al. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases. Mediators Inflamm. 2013, 391984 (2013).

  • 148.

    Nakamura, T. et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 98, 874–881 (2007).

  • 149.

    Sharma, M. D. et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117, 2570–2582 (2007).

  • 150.

    Bopp, T. et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 204, 1303–1310 (2007).

  • 151.

    Klein, M. & Bopp, T. Cyclic AMP represents a crucial component of Treg cell-mediated immune regulation. Front. Immunol. 7, 315 (2016).

  • 152.

    Borsellino, G. et al. Expression of ectonucleotidase CD39 by Foxp3+Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110, 1225–1232 (2007).

  • 153.

    Ring, S., Oliver, S. J., Cronstein, B. N., Enk, A. H. & Mahnke, K. CD4+CD25+regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. J. Allergy Clin. Immunol. 123, 1287–1296 (2009). e1282.

  • 154.

    Grossman, W. J. et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21, 589–601 (2004).

  • 155.

    Jones, T. G., Finkelman, F. D., Austen, K. F. & Gurish, M. F. T regulatory cells control antigen-induced recruitment of mast cell progenitors to the lungs of C57BL/6 mice. J. Immunol. 185, 1804–1811 (2010).

  • 156.

    Kwon, D. S. et al. CD4+CD25+regulatory T cells impair HIV-1-specific CD4 T cell responses by upregulating interleukin-10 production in monocytes. J. Virol. 86, 6586–6594 (2012).

  • 157.

    Taams, L. S. et al. Modulation of monocyte/macrophage function by human CD4+CD25+regulatory T cells. Hum. Immunol. 66, 222–230 (2005).

  • 158.

    Tiemessen, M. M. et al. CD4+CD25+Foxp3+regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl. Acad. Sci. 104, 19446–19451 (2007).

  • 159.

    Ganeshan, K. & Bryce, P. J. Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGFβ(). J. Immunol. 188, 594–603 (2012).

  • 160.

    Gri, G. et al. CD4+CD25+regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 29, 771–781 (2008).

  • 161.

    Baru, A. M. et al. Selective depletion of Foxp3+Treg during sensitization phase aggravates experimental allergic airway inflammation. Eur. J. Immunol. 40, 2259–2266 (2010).

  • 162.

    van de Veen, W. et al. Role of regulatory B cells in immune tolerance to allergens and beyond. J. Allergy Clin. Immunol. 138, 654–665 (2016).

  • 163.

    Braza, F., Chesne, J., Castagnet, S., Magnan, A. & Brouard, S. Regulatory functions of B cells in allergic diseases. Allergy 69, 1454–1463 (2014).

  • 164.

    Boonpiyathad, T. et al. High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers. Allergy 72, 407–415 (2017).

  • 165.

    van de Veen, W. et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J. Allergy Clin. Immunol. 131, 1204–1212 (2013).

  • 166.

    Flicker, S. & Valenta, R. Renaissance of the blocking antibody concept in type I allergy. Int. Arch. Allergy Immunol. 132, 13–24 (2003).

  • 167.

    Munro-Ashman, D., McEwen, H. & Feinberg, J. G. The patient self (P-S) test. Demonstration of a rise in blocking antibodies after treatment with Allpyral. Int. Arch. Allergy Appl. Immunol. 40, 448–453 (1971).

  • 168.

    Cuthbert, O. D. Application of the patient-self (P-S) test to assess the specificity of hyposensitization with Allpyral-G. Clin. Exp. Allergy 5, 271–277 (1975).

  • 169.

    Blair, H., Ezeoke, A. & Hobbs, J. R. IgE, IgG and patient-self tests during slow hyposensitization to grass pollen. Clin. Exp. Allergy 5, 263–270 (1975).

  • 170.

    Wilson, D. R. et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin. Exp. Allergy 31, 1705–1713 (2001).

  • 171.

    Ventura, I. et al. Allergen immunotherapy decreases LPS-induced NF-kappaB activation in neutrophils from allergic patients. Pediatr. Allergy Immunol. 25, 129–135 (2014).

  • 172.

    Aroca, R. et al. Immunotherapy reduces allergen-mediated CD66b expression and myeloperoxidase levels on human neutrophils from allergic patients. PLoS ONE, 9 e94558 (2014).

  • 173.

    Passalacqua, G. et al. Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. Am. J. Respir. Crit. Care Med. 152, 461–466 (1995).

  • 174.

    Yu, S.-J., Liao, E.-C. & Tsai, J.-J. Effects of local nasal immunotherapy in allergic airway inflammation: using urea denatured Dermatophagoides pteronyssinus. Hum. Vaccin. Immunother. 11, 915–921 (2015).

  • 175.

    Lao-Araya, M., Steveling, E., Scadding, G. W., Durham, S. R. & Shamji, M. H. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. J. Allergy Clin. Immunol. 134, 1193–1195 (2014). e1194.

  • 176.

    Hussey Freeland, D. M., Fan-Minogue, H., Spergel, J. M., Chatila, T. A. & Nadeau, K. C. Advances in food allergy oral immunotherapy: toward tolerance. Curr. Opin. Immunol. 42, 119–123 (2016).

  • 177.

    Johansen, P., von Moos, S., Mohanan, D., Kündig, T. M. & Senti, G. New routes for allergen immunotherapy. Hum. Vaccin. Immunother. 8, 1525–1533 (2012).

  • 178.

    Senti, G., von Moos, S. & Kundig, T. M. Epicutaneous immunotherapy for aeroallergen and food allergy. Curr. Treat. Options Allergy 1, 68–78 (2014).

  • 179.

    Hylander, T., Latif, L., Petersson-Westin, U. & Cardell, L. O. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J. Allergy Clin. Immunol. 131, 412–420 (2013).

  • 180.

    Senti, G., Johansen, P. & Kundig, T. M. Intralymphatic immunotherapy. Curr. Opin. Allergy Clin. Immunol. 9, 537–543 (2009).

  • 181.

    Yesil, O. et al. Intranasal and intragastric allergen immunotherapy prevented chronic histopathologic changes in a murine model of asthma. J. Allergy Clin. Immunol. 113, S210 (2004).

  • 182.

    Durham, S. R. et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J. Allergy Clin. Immunol. 129, 717–725 (2012). e715.

  • 183.

    Reich, K. et al. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen–induced rhinoconjunctivitis. Clin. Ther. 33, 828–840 (2011).

  • 184.

    Valenta, R., Campana, R., Focke-Tejkl, M. & Niederberger, V. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: lessons from the past and novel mechanisms of action for the future. J. Allergy Clin. Immunol. 137, 351–357 (2016).

  • 185.

    Spertini, F. et al. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J. Allergy Clin. Immunol. 134, 239–240 (2014). e213.

  • 186.

    Spertini, F. et al. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: results of a phase IIb study. J. Allergy Clin. Immunol. 138, 162–168 (2016).

  • 187.

    Pellaton, C. et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin. Transl. Allergy 3, 17–17 (2013).

  • 188.

    Creticos, P. S. Advances in synthetic peptide immuno-regulatory epitopes. World Allergy Organ. J. 7, 30 (2014).

  • 189.

    Marth, K. et al. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J. Immunol. 190, 3068–3078 (2013).

  • 190.

    Valenta, R., Campana, R., Focke-Tejkl, M. & Niederberger, V. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: lessons from the past and novel mechanisms of action for the future. J. Allergy Clin. Immunol. 137, 351–357 (2016).

  • 191.

    Maasch, H. J. & Marsh, D. G. Standardized extracts modified allergens—allergoids. Clin. Rev. Allergy 5, 89–106 (1987).

  • 192.

    Niederberger, V. et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. U. S. A. 101, 14677–14682 (2004).

  • 193.

    Jutel, M. et al. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol. Int. 62, 425–433 (2013).

  • 194.

    Focke-Tejkl, M. et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J. Allergy Clin. Immunol. 135, 1207-1217.e1211 (2015).

  • 195.

    Massanari, M. et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J. Allergy Clin. Immunol. 125, 383–389 (2010).

  • 196.

    Shi, Y. et al. Specific immunotherapy in combination with Clostridium butyricum inhibits allergic inflammation in the mouse intestine. Sci. Rep. 5, 17651 (2015).